Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives $57.50 Average Price Target from Brokerages

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) has been assigned a consensus recommendation of “Buy” from the six ratings firms that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation, three have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $57.50.

Several equities research analysts have weighed in on COLL shares. Needham & Company LLC restated a “buy” rating and issued a $56.00 target price (up from $54.00) on shares of Collegium Pharmaceutical in a research note on Thursday, March 19th. Wall Street Zen raised Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Zacks Research raised Collegium Pharmaceutical from a “hold” rating to a “strong-buy” rating in a report on Monday, June 29th. HC Wainwright reaffirmed a “buy” rating and issued a $60.00 price objective on shares of Collegium Pharmaceutical in a research report on Friday, March 20th. Finally, Truist Financial upgraded shares of Collegium Pharmaceutical to a “strong-buy” rating in a research note on Monday, June 15th.

Collegium Pharmaceutical Stock Down 1.6%

COLL stock traded down $0.58 during trading on Friday, reaching $35.23. 286,216 shares of the company traded hands, compared to its average volume of 434,726. The business has a 50 day simple moving average of $34.69 and a 200 day simple moving average of $38.81. Collegium Pharmaceutical has a 12 month low of $29.19 and a 12 month high of $50.79. The company has a debt-to-equity ratio of 2.47, a quick ratio of 1.62 and a current ratio of 1.71. The company has a market capitalization of $1.14 billion, a price-to-earnings ratio of 17.27 and a beta of 0.73.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 EPS for the quarter, topping analysts’ consensus estimates of $1.52 by $0.24. Collegium Pharmaceutical had a net margin of 9.41% and a return on equity of 95.18%. The business had revenue of $193.52 million during the quarter, compared to the consensus estimate of $184.47 million. During the same period in the previous year, the company posted $1.49 earnings per share. The firm’s revenue was up 8.9% on a year-over-year basis. On average, equities research analysts anticipate that Collegium Pharmaceutical will post 6.76 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of COLL. Group One Trading LLC purchased a new stake in Collegium Pharmaceutical in the fourth quarter valued at approximately $28,000. Caitong International Asset Management Co. Ltd lifted its position in Collegium Pharmaceutical by 205.3% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 635 shares of the specialty pharmaceutical company’s stock valued at $29,000 after purchasing an additional 427 shares during the period. PNC Financial Services Group Inc. grew its position in Collegium Pharmaceutical by 42.2% during the 1st quarter. PNC Financial Services Group Inc. now owns 1,408 shares of the specialty pharmaceutical company’s stock worth $47,000 after purchasing an additional 418 shares during the period. Kemnay Advisory Services Inc. purchased a new position in shares of Collegium Pharmaceutical during the 4th quarter valued at about $61,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Collegium Pharmaceutical by 26.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,536 shares of the specialty pharmaceutical company’s stock valued at $71,000 after buying an additional 318 shares during the period.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.